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This collaboration bachelor thesis focuses on cancer and how the drug metformin might be a future 
cancer treatment as it interrupt the cells metabolism by inhibition of complex I of the respiratory 
chain and numerous studies have shown that it affect cancer cells in many beneficial ways.  
There are numerous publications available regarding metformin effect in cancer cells, and part of our 
bachelor thesis involved extracting data from 66 scientific articles where metformin was used and 
cells were tested for viability, oxygen consumption rates (OCR) and extracellular acidification rates 
(ECAR) and more, which we organized in a database. The database now includes information of 
which glucose concentration was used in cell growth media, metformin concentration, which cell 
lines were used, viability before and after metformin treatment, treatment time and the results of 
the XF seahorse analyzer; OCR and ECAR which are measurements of cell metabolism.  
The aim was to use these data to create a model, using machine learning, that could predict cell how 
different cells would respond to metformin (viability) based on their metabolic data. Furthermore, 
we used two pancreatic cancer cell lines, Panc-1 and MIA-Pa-Ca-2 in lab experiments to test their 
sensitivity to metformin treatment using two different cell viability assays. 
The two different pancreatic cancer cell lines, Panc-1 and MIA-Pa-Ca-2 was exposed to the biguanide 
drug metformin in three different concentrations. To be within the sensitivity of the assay, three cell 
viability assays was done in advance of the metformin experiment and showed that 10 000 cell/well 
was the best option. Both cell lines were seeded out as 10 000 cell/well on a 96-well plate before 
exposure to metformin. The cells were treated with three different metformin concentrations, 1 mM, 
5 mM and 10 mM respectively, and incubated for 24 hours and 48 hours.  
The results from the metformin treatment of the two cell lines showed that metformin does affect 
the cells as the cell viability decreased when the metformin concentration increased. The cells that 
was treated for 24 hours had much higher viability than those treated for 48 hours, so the most 
efficient treatment time was 48 hours. There were some deviations, especially for the Panc-1 cell 
line, but this was most likely due to errors done when preparing the plates. The MIA-Pa-Ca-2 cell line 
seemed to be more affected by 48 hours metformin treatment than Panc-1 cells, but the Panc-1 cells 
were more affected by 24 hours metformin treatment compared to MIA-Pa-Ca-2 cells based on 
results from this experiment.  
The machine learning part was not very successful as the model did not give good predictions 
compared to the result. These results might have been different if done by someone with more 






1. Introduction  
1.1 Cancer  
Cancer is the name of a collection of diseases that occurs when cells undergo abnormal cell growth 
and proliferation and spread to surrounding tissues. Cancer is one of the leading causes of death by 
disease in the world, so trying to understand this disease is a large field in science. In recent decades, 
the understanding of cancer diseases has developed at an incredible pace (Nature 2021) and the 
development and discovery of new treatments is improving rapidly. Understanding our cell’s life 
cycle and metabolism is crucial for understanding the development of cancer. The cells in our bodies 
are highly complex and their life cycles involve numerous of regulations. When these regulations are 
disrupted, the normal cell processes break down and cancers may develop. Cancer is a genetic 
disease, changes and mutations in the cells genetics that controls certain functions, especially the 
cells life cycle, can cause cancer (National Cancer Institute 2021b).  
The etiology of cancer is still being researched, but carcinogens such as cigarettes or radiation are 
well known to trigger cancer development. Other factors that might cause cancers are viruses and 
other infections, alcohol, poor diet, and little activity. Since cancer is a genetic disease, it can also be 
inherited and thus make some individuals more prone to develop cancer. The disease occurs in all 
age groups, but aging is definitively a risk factor. The elderly population is at greater risk for 
developing the disease. Cancer cells can develop in any kinds of tissues in the body, but the most 
common cancers are lung, breast, and prostate cancer. There are many different cancer therapies 
available, the most common being surgery, radiation, and chemotherapy. Some also gets targeted 




Figure 1.1: Cancer therapy approaches (Ecancer 2021) 
This figure shows the most innovative cancer therapies, different disciplines combined to get the most efficient 
and personalized therapy for the patient. These therapies are radiomics and pathomics, nanomedicine, 
extracellular vesicles, natural antioxidants, targeted therapy and immunotherapy, gene therapy, thermal and 




In this project our focus will be on pancreatic cancer which is one of the deadliest types of cancer. 
This aggressive cancer has the highest mortality rate in developed countries. It is more common for 
patients over 60 to get this type of cancer than middle age patients. The median age are 73 years. 
(Sarnecka et al. 2016).  
Pancreatic cancer normally occurs for two reasons, environmental and genetic risk factors. The 
environmental can be smoking, diabetes, high fat consumption and alcohol abuse. Genetic risk 
factors can be age, family history, ethnicity and genetic factors. (Rawla et al. 2019).  
1.1.1 The pancreas and pancreatic cancer 
The pancreas lies behind the stomach in the upper abdomen. It looks like a 15 centimeters long pear 
on the side, the bigger part is called head, the middle part is called body and the thin last part is 
called tail (National Cancer Institute 2021a) 
The pancreas is a gland, and its two main functions are control energy consumption and metabolism. 
The organ has two parts, one part is the exocrine pancreas and the other is the endocrine islets. The 
exocrine pancreas is a reservoir of digestive enzymes and the endocrine islets are the source of the 
vital metabolic hormone insulin (Zhou and Melton 2018).  
The exocrine pancreas produces acinar cells and ductal cells. Acinar cells produce among other 
lipases, proteinases and amylases. These are secreted and transported to the intestine to break 
down fat, proteins and carbohydrates. 
The endocrine pancreas constitutes less than 5% of the whole pancreas. This endocrine part of the 
pancreas also has more than a billion cells, and the major cells that gets synthesized and secrets are 
insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin. Insulin and glucagon are 
released directly into the blood system to regulate the blood glucose levels (Zhou and Melton 2018) 
There are two tumor types of pancreatic cancer that are the most common, it is adenocarcinoma 
who is in the exocrine part (around 85% of the cases) and pancreatic endocrine tumor (less than 5% 
of the cases) (Rawla et al. 2019). The endocrine tumors are called pancreatic neuroendocrine tumors. 
In this project there was studied two pancreatic cancer cell-lines. The first one is Panc-1 from a 56 
year old male, the growth properties were adherent. The other cell-line we used were MIA-Pa-Ca-2 
from a 65 year old Caucasian male, also here the growth properties was adherent. Both cell-lines 




Figure 1.2: Location of pancreas in the abdomen (Medicalnewstoday 2020) and picture of two pancreatic cell 
lines 
This figure shows the location of the pancreas in the abdomen and microscope pictures of the two pancreatic 
cells lines Panc-1 (to the right) and Mia-Pa-Ca-2 (to the left). This pancreas is the pink colored organ in the 
figure (Medicalnewstoday 2020). 
 
1.1.2 Cancer metabolism  
Cancer cells alter their metabolism to grow and proliferate rapidly, so they need to utilize glucose for 
generation of adenosine tri phosphate (ATP) differently than normal healthy cells, a phenomenon 
known as the Warburg effect (Warburg et al. 1927). In this section we will describe the basics in how 
normal cells utilize glucose, and then see how cancer cells adapt and changes their metabolic activity 
to support anabolic growth.  
1.1.3 Normal cell metabolism 
Normally cells utilize glucose by cellular respiration, that can be divided into four main steps. That is 
glycolysis, pyruvate oxidation, the citric acid cycle (TCA-cycle) and oxidative phosphorylation. In 
glycolysis the six-carbon sugar glucose is converted into two molecules of pyruvate, a three-carbon 
molecule. Glycolysis requires energy in the form of two ATP, and it generates four ATP, giving a net 
production of two ATPs. Glycolysis also converts two molecules of oxidized nicotinamide adenine 
dinucleotide (NAD+) to Nicotinamide adenine dinucleotide (NADH). In the absence of oxygen, the 
pyruvates formed through glycolysis gets rerouted into a process called fermentation. This process 
requires more NAD+ to keep the glycolysis process going. Thus, fermentation frees up some of the 
NAD+, resulting in the product lactic acid. If oxygen is present, the two molecules of pyruvate 
produced in glycolysis goes into the mitochondrial matrix where its converted into a two-carbon 
molecule bound to Coenzyme A (acetyl CoA). Here carbon dioxide is released and NADH is also 
generated. In the citric acid cycle, the acetyl CoA created by pyruvate oxidation combines with a 
four-carbon molecule, and then it goes through a large series of reactions and ends up with 
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regenerating the four-carbon molecule the circle started with, which can enter a new cycle. This cycle 
of reactions produces ATP, NADH and reduced flavin adenine dinucleotide (FADH2) and releases 
carbon dioxide. The last step in cellular respiration is oxidative phosphorylation. This is where most 
of the ATP is produced. The NADH and FADH2 produced in the earlier steps now deposit their 
electrons into the electron transport chain, see figure 1.3. The electrons move down a chain of 
complexes, releasing energy which is used to pump protons out of the mitochondrial matrix, and into 
the intermembrane space, creating a gradient. The protons then flow back into the matrix through 
the enzyme ATP-synthase and ATP are produced. In the end of the chain, oxygen molecules accept 
the electrons and takes up protons forming water molecules. Oxidative phosphorylation produces up 
to 36 ATP molecules per glucose molecule (Khan Academy 2021).  
 
Figure 1.3: Normal cell metabolism (Khan Academy 2021) 
This figure shows the main basic steps of how normal cells utilize glucose for energy production through 
aerobic glycolysis, pyruvate oxidation, the TCA cycle and at last oxidative phosphorylation in the electron 
transport chain. In glycolysis the glucose molecule undergoes a series of chemical transformations and is 
converted into two molecules of pyruvate, this process requires ATP and produces ATP and NADH. The 
pyruvate is then oxidized in the mitochondrial matrix and converted into a two-carbon molecule bound to 
acetyl-CoA. CO2 is released and NADH is generated. In the citric acid cycle the acetyl-CoA is combined with a 
four-carbon molecule and undergo a series of reactions that regenerates the four-carbon molecule that can 
combine with a new acetyl-CoA and enter the cycle again. The TCA cycle produces ATP, NADH and FADH2 and 
CO2 is released. Oxidative phosphorylation in the last step in the series of reactions in cells utilization of 
glucose, and this is where the most ATPs are produced. It occurs in the inner membrane of the mitochondria. 
The NADH and the FADH2 releases electrons into the electron transport chain. As the electrons moves down 
the chain, energy is released and protons are pumped into the intermembrane space of the mitochondria, 
creating an electrochemical gradient between the mitochondria matrix and intermembrane space. The protons 
flow back into the matrix trough the enzyme ATP synthase, making ATP. At the end of the electron transport 




1.1.4 Cancer metabolism – the Warburg effect 
Cancer cells on the other hand alter their metabolism to proliferate rapidly. The common feature of 
cancer cells altered metabolism is the increased glucose uptake and fermentation of glucose to 
lactate, even if they have a fully functionating mitochondria and when oxygen is present. This 
phenomenon is known as the Warburg effect and was discovered by the Nobel prize winner Otto 
Warburg in the 1920s (Warburg et al. 1927). The question is, why do proliferating cells switch to a 
less efficient way to produce ATP? Compared to the amount of ATP generated through mitochondrial 
respiration, per unit glucose, aerobic glycolysis is inefficient, but the rate of glucose metabolism in 
aerobic glycolysis is higher. That is, production of lactate from glucose occurs 10-100 times faster 
than the complete oxidation of glucose in the mitochondria (Liberti and Locasale 2016). Hence, this 
way of producing ATP is comparable to complete oxidation of glucose in the mitochondria. A theory 
is that cells with a higher rate, but lower yield of ATP production might have selective advantages 
when competing for nutrients (Liberti and Locasale 2016). A study found that when changes to the 
cells environment were exposed to greatly increase in ATP demand by altering the demand of ATP-
dependent membrane pumps, aerobic glycolysis increased rapidly and oxidative phosphorylation 
remained constant (Liberti and Locasale 2016). This supports the supposed advantages of aerobic 
glycolysis in cancer cells. These metabolic alterations enable cancer cells to live in conditions of 
fluctuating oxygen tension that would be lethal for cells that rely on oxidative phosphorylation 
(Kroemer and Pouyssegur 2008).  
When cancer cells generate lactic acid through glycolysis, such acidic conditions change their 
environment, and thus favor tumor invasion and even suppresses anticancer immune effectors. 
Stromal cells can take up lactic acid produced by tumor cells which regenerate pyruvate that can be 
used to refuel cancer cells or can be used in oxidative phosphorylation (Kroemer and Pouyssegur 
2008). This generates a microecosystem where anaerobic and aerobic components engage in 
complementary metabolic pathways and recycles products of anaerobic metabolism. This sustains 
cancer cells survival and proliferation (Kroemer and Pouyssegur 2008). Tumors can also generate 
nicotinamide dinucleotide phosphate (NADPH) through the pentose phosphate pathway (PPP) by 
metabolizing glucose. NADPH ensures cells antioxidant defense and therefore protects the cells 
(Kroemer and Pouyssegur 2008). NADPH is also used for fatty acid synthesis (Kroemer and 
Pouyssegur 2008). Cancer cells use a large amount of glucose as a carbon source for anabolic 
reactions, and they can also use intermediates of the glycolytic pathway (Kroemer and Pouyssegur 
2008). All these alterations help cancer cells to survive and divide in nutrient deplete conditions and 
proliferate rapidly.  
Tumor mitochondria are usually relatively small, lack cristae and are deficient in the β-F1 unit of the 
ATP-synthase, which defects the oxidative phosphorylation and can help to explain the mechanisms 
of metabolic reprogramming of cancer cells (Kroemer and Pouyssegur 2008). However, the molecular 
mechanisms that underlie metabolic reprogramming of cancer cells are very complex. Mitochondria 
DNA (mtDNA) mutations might contribute to tumor progression or be a result of tumor progression. 
Expression on mutant mtDNA-encoded NADH dehydrogenase subunit 2 as a nuclear, mitochondria-
targeted gene product stimulates aerobic glycolysis, production on reactive oxygen species and 




Figure 1.4: Illustration of the Warburg effect (Zhang et al. 2015). 
This figure shows the prominent aspects of the Warburg effect like glycolysis, TCA cycle, lactate fermentation, 
glutamine metabolism, penthouse pyruvate pathway and the intermediates of the TCA cycle used to synthesize 
lipids, nucleotides and amino acids. The yellow boxes show pivotal metabolic pathways and the red circles 
illustrates the enzymes controlling key steps. Abbreviations: GLUTs: glucose transporters; MCT: 
monocarboxylate transporter; PDC: pyruvate dehydrogenase complex; PDKs: pyruvate dehydrogenase kinases; 
LDHA: lactate dehydrogenase A; HIF1: hypoxia inducible factor 1, IDH: isocitrate dehydrogenase; SDH: 
succinate dehydrogenase, FH: fumarate hydratase (Zhang et al. 2015). 
 
1.2 Metformin 
Metformin is a widely used biguanide drug used to treat type 2 diabetes due to its ability to decrease 
plasma glucose. It has been used for over 60 years, has few side effects and is considered safe, 
moreover it has relatively low cost. Discovery of the different effects of metformin have encouraged 
researchers to further study the drug, to see if it might have therapeutic effect on a variety of other 
diseases (Lv and Guo 2020). It is stated that metformin has shown benefits in diseases including 
cancers such as breast cancer, endometrial cancer, bone cancer, colorectal cancer and melanoma (Lv 
and Guo 2020). Metformin also showed benefits in diseases such as obesity, liver diseases, 
cardiovascular disease, renal disease and even in aging (Lv and Guo 2020).   
Metformin is a derivate of galegine which is a natural product from the plant Galega officinalis that 
have been used as an herbal medicine in medieval Europe. In the 1920s galegine was found to be a 
glucose-lowering agent but was also found to be toxic. In this period both Metformin and 
Phenformin were synthesized and tested, and in 1950 they were introduced to clinical use. Galegine 
is chemically an isoprenyl derivate of guanidine. Metformin and Phenformin are biguanides 




Studies show that physiologically, metformin reduce gluconeogenesis, but not all its effect can be 
explained by this (Rena et al. 2017). The findings are also dose and treatment time dependent, with 
differences between acute and chronic administration. At molecular levels, metformin act via both 
AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms. It inhibits 
mitochondrial respiration, but it seems to also inhibit mitochondrial glycerophosphate 
dehydrogenase which is a mechanism involving the lysosomes (Rena et al. 2017). The effects of 
metformin are due to affecting different signaling pathways, however the underlying mechanisms is 
still not fully understood (Lv and Guo 2020).  
 
 
Figure 1.5: Chemical structure of metformin (PubChem 2021) 
This is a 2D figure of the chemical structure of the drug metformin. 
 
1.2.1 Metformin effect on cancer metabolism 
The hypothesis that biguanides could be used for disease treatment was raised when phenformin 
was introduced and used to treat type 2 diabetes (Saraei et al. 2019). Phenformin was later shown to 
be toxic. Further studies raised the question if these types of drugs could be used for cancer 
treatment. Due to the toxicity of phenformin, metformin was the best candidate for cancer 
treatment trials. Recent studies and analysis have shown that metformin can reduce the proliferation 
of cancer cells and that the possibility of malignancies in a variety of cancer types also reduces 
(Saraei et al. 2019). These types include cancers such as breast, colon, prostate and pancreas. It has 
also been shown that metformin can be a promising candidate in combination treatment, along with 
radiotherapy metformin reduced tumor growth in cancers such as ovarian and melanoma. (Saraei et 
al. 2019)  
One of the most intensively studied mitochondrial actions of metformin, which also is important for 
our study, is the inhibition of Complex I of the respiratory chain, see figure 1.6 (Rena et al. 2017). This 
suppresses ATP production from oxidative phosphorylation and affects the cells metabolism and 
triggers the cells adaptive energy-saving measures, involving downregulation of macromolecule 
synthesis. Mitochondrial inhibition also triggers the liver to compensate for the changes and lower 
the glucose release. This reduces the plasma glucose and insulin levels, as well as insulin-like growth 
factors and cytokines. These changes have shown to establish a less favorable environment for 
cancer cells and their proliferation. An important thing to notice is that these observations have not 
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only been seen in patients with diabetes, but it has also been observed in patients without diabetes 
(Rena et al. 2017).  
 
Figure 1.6: Metformin’s effect on cancer cells (Vial et al. 2019)  
This figure shows the mitochondria mechanisms of action of metformin. The drug is taken up by the cell, 
mostly through OCT1 in hepatocytes, and metformin’s primary target is the mitochondria, it exerts specific 
inhibition on complex 1 of the respiratory chain through interaction with the ND3 core subunit and 
mitochondrial glycerophosphate dehydrogenase. When complex 1 is inhibit the NADH oxidation, proton 
pumping across the mitochondrial membrane and oxygen consumption rate decreases. This results in a lower 
gradient across the membrane and reduces proton-driven ATP synthesis from inorganic phosphate and ADP. 
When the mitochondrial glycerophosphate dehydrogenase is inhibited it modulates cytosolic and 
mitochondrial redox state which increases cytosolic NADH, adenylate cyclase and fructose-1,6-bisphosphate 
(Vial et al. 2019). 
 
As mentioned earlier in this thesis, the exact mechanisms underlying the actions of metformin are 
still not clearly identified. The effect of the drug can vary due to the way it is used, if it is used alone 
or in a combination treatment with for example chemotherapeutic drugs, and the effect is also dose 
dependent (Chen et al. 2020). What we do know today is that a potent anticancer property of 
metformin is due to the activation of the LKB1-AMP-activated protein kinase (AMPK) signaling 
pathway. The drug increases the ratio of adenosine mono phosphate (AMP) to adenosine tri 
phosphate (ATP) by targeting complex I of the mitochondrial respiratory chain and thus activate the 
upstream kinase LKB1 that phosphorylates and activate AMPK. This activation can suppress 
mammalian target of rapamycin complex which are important in cell growth, proliferation and 
metabolism (Chen et al. 2020). Metformin can also inhibit complex I and mTORC1 activity in an 
AMPK-independent way, and metformin-induced activation of AMPK promotes PD-L1 
phosphorylation which results in endoplasmic reticulum-associated PD-L1 protein degradation, and 
thus allows an cytotoxic T-lymphocyte mediated tumor cell death (Chen et al. 2020).  
From the 2019 study by Saraei et al. there is listed a short brief of six effects of metformin based on 
various reputable published data and articles. See table 1.1 for effects (Saraei et al. 2019). Saraei et al 
also writes that metformin, due to all the benefits listed above, is an ideal candidate for cancer 
prevention, improvement in different treatments and preventing malignancy of tumors. 
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Table 1.1: the main effects of metformin on cancer cells (Saraei et al. 2019). 
This table lists up the beneficial effects of metformin on cancer cells. All the information was found in the 2019 
article by Saraei et al. 
 The effects of metformin 
1 Reduce the chance of cancer incidence 
2 Reduce mortality of different cancers 
3 When used in combination treatment with 
radiotherapy and chemotherapy, metformin 
increases the response 
4 Reduces tumor malignity 
5 Reduce likelihood for relapse 
6 Reduces the damaging effects of androgen 
derivatives (ADT) 
 
1.3 Database and Citavi 
Metformin’s effect on cancer cells have been researched for a long time, and there have been 
published numerous of scientific articles about the subject. This research holds valuable information 
for our research as well as for future studies. Extracting interesting data from different articles to 
make a database with important information was done by using a computer program named Citavi. 
66 different articles were chosen, all of them having a common denominator being metformin, 
cancer cells metabolism and the “seahorse XF analyzer”, which is an instrument used in measuring 
the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in live cells. As 
these measurements gives a good indication of how metformin effects the cancer cells metabolism, 
these results were of interest. Other parameter such as glucose concentration, metformin 
concentration, treatment time, viability, cell line and normalization method (of the seahorse XF 
analyzer) was also collected. Machine learning was used to interpret this data. 
1.4 Seahorse XF 
Seahorse XF analyzer is an instrument used in measuring the oxygen consumption rate (OCR) and the 
extracellular acidification rate (ECAR) in live cells. The OCR and ECAR gives information about the 
metabolism in the cells. The OCR gives a measure of mitochondrial function and is a marker of factors 
triggering the switch from healthy oxidative phosphorylation to aerobic glycolysis in cancer cells. The 
ECAR determines glycolysis by measuring the extracellular acidification rate of surrounding tissues, 
the excretion of lactic acid after its conversion from pyruvate (Agilent 2020). 
1.4.1 Modulators in Seahorse XF analyzer 
To find the OCR the seahorse XF analyzer adds modulators of respiration into the wells to find out 
the key parameters of mitochondrial function. The modulators are Oligomycin, Carbonyl cyanid-4 




Figure 1.7: Seahorse XF cell mito stress test profile (Agilent 2020) 
This figure shows the expected oxygen consumption rate in pmol/min in the mitochondrial respiration when 
the modulators oligomycin, FCCP, Rotenone and antimycin A are added (Agilent 2020). 
 
The modulators who been adding are targeting the electron transport chain (ETC) in different ways. 
For example, Oligomycin inhibits complex 5 where ATP synthase is happening. FCCP are uncoupling 
the proton gradient generated by the mitochondrial membrane. The Rotenone are inhibiting the 
complex 1 by blocking the electron transfer from iron-sulfur centers in the complex (Heinz et al. 
2017). Antimycin blocking the passage of electrons from cytochrome b to cytochrome c, thereby it 
inhibits the electron flow true complex 3 (Maria Ahmad et al. 2020), see picture 1.8 for an overview.  
 
Figure 1.8: overview of the electron transport chain (Agilent 2020). 
All modulators from the seahorse XF cell Mito stress test and all complexes in ETC are shown, the signs show 




1.5 Machine learning  
Machine learning is an application of artificial intelligence with a primary aim of allowing the 
computer to learn automatically. It enables systems to learn and improve from previously 
experiences without being programmed (Expert.ai 2020). Machine learning holds a collection of 
data-analytical techniques with a purpose for building predictive models from multi-dimensional 
datasets. In medicine, machine learning is a growing field with many resources. It has the ability to 
deal with large and complex data which is often found within the medical field, and possibly is the 
future for biomedical research, personalized medicine, computer-aided diagnosis to significantly 
advanced global health care (Handelman et al. 2018). It is also becoming integral to modern 
biological research as it allows generation of models that learns from very large datasets and can 
make predictions based on these data. (Camacho et al. 2018).   
As mentioned, machine learning gives the computers the ability to learn without first being 
programmed. This is done by introducing algorithms that ingest input data, use computer analysis for 
predicting values within an acceptable range of accuracy, identifying patterns in the data and learn 
for previously experiences. The idea of using machines to elucidate patterns and conclusions that are 
very difficult to reach by conventional statistical methods and that needs to be done manually by 
human operators is extremely relevant for the future. With machine learning this process is 
semiautomated, the computer is provided data and creates complex analytical models using learning 
framework to optimize the accuracy of prediction. (Handelman et al. 2018). Machine learning is not 
very different from conventional statistics, it is based on or adopts statistical underpinnings to how it 
works, but if much more efficient. 
1.5.1 Machine learning basics 
The data used in a machine-learning algorithm typically consists of parameters called “features” and 
“labels” across a set of samples. Features stands for the measurements across all samples and can be 
raw data or be transformed mathematically. Labels stands for the outcome that the models aim to 
predict, the outcome of the model. Machine learning algorithms may also interpret datasets lacking 
labels, see figure 1.9. The general workflow in machine learning is to first process the input data, 
then learn and/or train the model using a set of mathematical formulas and statistics, and at last use 
the model to predict a label of interest. The learning process consists of finding the optimal 
parameters for the model that translates the features from the data to accurate predictions of the 
labels. These parameters are estimated through a series of back and forth steps. Frist estimation, 
then the performance is evaluated, and errors are corrected, and new estimations are made and 
evaluated again. This is the process referred to as “training”, and it will repeat until the model 
performance can’t be further improved, which is assessed my error minimization. When the 
parameters are optimized the model can be used to predict outcomes of the model using new data 






Figure 1.9: Machine-learning used to interpret and analyze datasets to build models 
Example of how machine learning can be used to interpret data, here genes, proteins, and metabolites. The 
data consist of features that is measured over many samples and edges within networks. The machine-learning 
approach is selected based on properties of the data. If the data are unlabeled an unsupervised approach 
should be used, and if the data are labeled a supervised approach should be used and will generate a predictive 
model. After applying the most appropriate approach, the predictions made have to be validated. New data 
can be collected and used to refine the learned model and improve the performance (Camacho et al. 2018).        
 
1.6 Muse® Count & Viability kit (200X) 
To count and check the viability of the cells Muse® Count and viability kit (200X) were used. This 
machine finds viable cell count (cells/mL), total cell count (cell/mL) and precent viability of the 
sample. To do so the cell sample need to be mixed with Muse® Count & Viability reagent (200X) to 
get a DNA-binding dye in the reagent so it stains cells. Then it will be showing the result in a dotplot 
on the screen how much viable cells and non-viable cells it is. Another dye in the reagent are a 
membrane-permeant DNA staining dye that will stain all cells with a nucleus this will also be shown 
as a dotplot on the screen, see figure 1.10. This will discriminate cells from cells with a nucleus from 
non-nucleated cells and debri (Luminex Corporation 2020b). 
 
Figure 1.10: Illustration of the screen of the Muse count and viability machine (Luminex Corporation 2020a) 
an illustration of how the result can look like on screen on the Muse Count & Viability machine (Luminex 
Corporation 2020a). The red dots illustrate nucleated cells, live (on the left) and dead (on the right). The green 




This system is a high-performance cell analyzing using a microcapillary technology. It has laser-based 
fluorescence detection and each cell event can evaluate up to three cellular parameters, see figure 
1.11. (Luminex Corporation 2021). 
 
Figure 1.11: Illustration of how a cell samples viability is measured in the muse count and viability machine 
(Luminex Corporation 2020a) 
The cell sample is loaded in a small tube and inserted into the machine. A green diode laser is used for 
excitation and each cell event can evaluate up to three cellular parameters cell size, detection in red color and 
detection in yellow color channels (Luminex Corporation 2021).  
 
1.7 Aseptic cell culturing techniques 
In labs, cells are grown “in vitro”, which means they are grown outside a living organism. Cancer cells 
are typically grown in flasks with growth media containing important ingredients for their survival 
(see section 2). The cells are kept in an incubator at appropriate temperature, human cells at 37°C to 
mimic body temperature. To keep the cells alive and comfortable, one must provide constant 
nutrients, so the medium in the flasks are aspirated regularly and new media is added. The cells are 
also passaged when they approach a certain confluency to avoid competition for nutrients and 
unwanted signaling between the cells. When working on cells in the lab aseptic techniques are used 
to keep the cells free from pathogens and avoid any contamination. The cell lab should be clean and 
kept as sterile as possible. All work should be done in a sterile fume hood. In this project a “LAF 
cabinet” was used. This is a sterile fume hood that has a laminar air flow that protect the cells from 
the user. This cabinet is not connected to a special ventilator that protects user from toxins, but 
when working on cells this is not needed, except when toxins are used as well. This kind of cabinet is 
crucial for working in a complete sterile environment. When working on cells one should also use 
gloves, protection clothing and face mask. Disinfection in the form of ethanol can be used to sterilize 




1.7.1 Phosphate-Buffered Saline (PBS), Trypsin and media  
Phosphate buffered saline (PBS) is used to wash the cells under passaging and is a non-toxic solution 
that prevents cells from shriveling or rupturing due to osmosis (Martin et al. 2006). In the culturing 
flasks cells adhere to the walls by proteins in the extracellular matrix. These proteins need to be 
digested by the enzyme trypsin before cell passage to break up adherent cells. Trypsin is a protease 
found in the digestive system of many vertebrates that hydrolyses proteins to polypeptides. The 
enzyme usually cuts the peptide chains in the carboxyl side in the amino acids’ arginine or lysine. The 
proenzyme for trypsin is secreted from the pancreas and is activated in the duodenum. Trypsin is due 
to its efficacy and low cost used in numerous biotechnological processes (Store medisinske leksikon 
2021). Under cell passaging the trypsin should not be let to digest for too long as this can result in 
damage to the cells. Therefore, inactivation of the enzyme after breaking up adherent cells is 
important. This can be done by fetal bovine serum which is a widely used serum in cell culture 
medium. In this experiment the serum was added to the medium used to contain cells in, that is 
described in the methods section. Fetal bovine serum contains anti-trypsin which is a substance that 
inactivates the trypsin and thus stop the digestion. L-glutamine and streptomycin was also added. L-
glutamine is an amino acid supplement added to support growth in a cell culture and streptomycin is 
an antibiotic that protects the cell culture from bacteria.   
 
1.8 Measuring cell viability 
1.8.1 AlamarBlue 
For over 50 years the reagent alamarBlue has been used for studies of cell viability and cytotoxicity in 
many different biological and environmental systems. The substance is widely used and generally its 
use has been applied to various aspects for monitoring cellular health, cell cycle, apoptosis, test 
compound toxicology in medicine, cytotoxicity and antimicrobial susceptibility testing (Rampersad 
2012). In this project the alamarBlue was used to measure cell viability before and after metformin 
treatment.   
The reagent can monitor the reducing environment of the living cell. Resazurin is the active reagent 
in alamarBlue and this is a water-soluble, non-toxic, stable in culture media and permeable through 
the cell membranes. This makes one able to continuous monitor the cells in the culture. Resazurin is 
a blue non-fluorescent dye that can be reduced to the pink colored, highly fluorescent resorufin, see 
figure 1.12. The reagent also acts as an intermediate electron acceptor in the electron transport 
chain without interfering with the normal functions of the chain. The indicator dye changes from the 
oxidized, non-fluorescent blue form to the reduced pink form when it accepts electrons. (Rampersad 
2012) 
Due to the changes of the resazurin from its oxidized to its reduced state, the reagent is very flexible 
when it comes to quantitative measurements as colorimetric and fluorometric readings, or 
qualitative as there is a visible change in color that indicates the presence of viable cells. The 
spectrometric absorbance can be taken at two wavelengths (570 nm and 600 nm or 540 nm and 630 
nm). The fluorescence signals can be measured at excitation wavelength at 530-560 nm and an 
emission wavelength at 590 nm. (Rampersad 2012)    
The culture media used in this kind of assay must be buffered as the optimal pH for the reagent is 
between 7.0 and 7.4. The optimal temperature for incubating the assay plate is 37°, and incubation 
should be done in the dark as alamarBlue is photosensitive. It is also important that the cell culture 
medium and all other reagents used in the assay does not interact with the assay chemistry. To avoid 
artifacts or false positive signals, the positive and negative controls should be empirically 
determined. The endpoint of the assay depends on which cell density was used. Cells in the assay 
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should be in exponential stage of growth and the medium should be synthetic and defined, but it 
have to allow sufficient growth so that inhibitory or stimulatory effects of compounds tested are not 
exaggerated or underestimated. (Rampersad 2012) 
For this project the alamarBlue assay was very useful for the viability assay as it is easy to use and 
gives good results. The viability in two different cell lines, Panc-1 and MIA-Pa-Ca-2, was measured 
before and after metformin treatment. This was done by measuring the fluorescence signal at 
excitation wavelength at 540-590 nm using a SpectraMax® Paradigm® Multi-Mode Microplate 
reader, see figure 1.12. 
 
 
Figure 1.12: AlamarBlue resazurin reduction and equipment for measuring cell viability (ABP Biosciences 
2021). 
This figure shows the chemical composition of resazurin which is active reagent in alamarBlue. This reagent 
acts as an intermediate electron acceptor in the electron transport chain without interfering with the normal 
functions of the chain. When Resazurin accepts electrons, it is reduced to the pink, highly fluorescent resorufin 
that can be detected by a machine that can detect fluorescence and absorbance. Cell cultures are typically 
seeded out on a plate containing wells shown in the figure. This plate can be inserted to the machine directly 
and shows the results on an external screen (ABP Biosciences 2021).  
 
1.8.2 CCK-8 
The CCK-8 cell counting kit utilizes Dojindo’s highly water-soulable tetrazolium salt and allows for 
very convenient assays. WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4- disulfophenyl)-
2H-tetrazolium, monosodium salt] produces a formazan dye which is very water-soluble and that in 
the presence of an electron mediator is reduced, see figure 1.13. It is nonradioactive and allows 
sensitive colorimetric assays for determination viable cells in cell proliferation and cytotoxicity 
assays. As shown in figure 1.13, WST8 is reduced by dehydrogenases in the cells and gives the orange 
colored product formazan. This product is soluble in the tissue culture medium. The number of viable 






Figure 1.13: CCK-8 cell viability kit (Phd 2016) 
The figure describes how the CCK-8 assay affect the cell and shows the chemical structure of the reagent 
before and after reduction. WST-8 (Dojindo’s highly water-soluble tetrazolium salt is reduced to a yellow-color 
formazan dye by dehydrogenase activities in the cells. This dye is soluble in the tissue culture media. The 
number of viable cells is directly proportional to the amount of formazan dye (Phd 2016).   
 
1.9 SpectraMax® Paradigm® Multi-mode Microplate reader 
To measure cell viability a multi-mode microplate reader was used which can read fluorescence or 
absorbance across different wavelengths. These instruments are equipped with a Xenon flash lamp 
that can excite the fluorophore resorufin to be read at the appropriate emission wavelength. For the 
resazurin alamarBlue the machine read at 540 nm through the well and adjusted for background 
using the reference wavelength of 590 nm. Fluorescence can be explained by the absorption of light 
energy and its transformation into emission light. The light that is emitted has longer wavelength and 
is lower in energy than the light which is coming in, that is why the emission light always is higher 
wavelength (BMGLabtech.com 2021b).  
When the machine measures the absorbance, it measures how much light is absorbed when the light 
goes through the sample. The machine quantifies the amount molecules in the solution which been 
absorbed of the light when the rest of the light hitting the detector on the other side 
(BMGLabtech.com 2021a). Formazan dye CCK-8 absorbance is read at wavelength 450 nm.  
1.10 Aim for this project  
In this collaboration bachelor thesis, we will focus on how understanding cancer cells metabolism can 
help us to develop better treatments for cancer patients. The understanding of how cancer cells 
reprogram and utilize glucose differently than normal cells is an important part of the development 
of new cancer treatments. Our main research is to study how the biguanide drug metformin can 
affect the metabolism in cancer cells, and therefore might be a future cancer treatment.  
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2. Materials and methods  
2.1 Materials 
All materials and chemicals used in this project were provided from associate professor Hanne 
Røland Hagland and her lab team. For clarity, everything is listed in tables, see table 2.1 and 2.2. 
Description of how the materials and chemicals was used will be in the coming section.   
 
Table 2.1: Table of all the chemicals used in this project 
This table lists chemicals with the corresponding producer/company and associated product number. 
Product Company Product number 
DMEM (Dulbecco’s Modified 
Eagle’s Media) without 
glucose, L-glutamine and 
sodium pyruvate 
Corning 17-207-CV 
Foetal bovine serum, heat 




solution 6,0/10,0 g/L 100X 
Biowest L0022-100 
Trypsin EDTA 1X Corning 25-053-Cl 
L-glutamine, 200mM Corning 25-005-Cl 
PBS tablet ThermoFisher 189112-014 
dH2O   
MIA-Pa-Ca-2  ECACC General Collection ECACC 85062806 
Panc-1  ATCC ATCC® CRL-1469 
AlamarBlue VWR MFCD00005036 
CCK-8 Tebu-bio CK04-05 
Metformin Alfa Aesar N27F021 
  
 
Table 2.2: Materials used in this project 
In this table the most important materials used in this project is listed. 
Sterile bench  Microscope 
Rack for tubes 96-wells plate  
50 mL tube T75 flasks 
15 mL tube  Water bath  
Eppendorf tube Incubator 
Automat pipette Fridge 
Pipettes for automat pipette  Freezer 
Pipette controller Aspiration-machine 





2.2.1 Metformin seahorse XF dataset 
In this project a dataset containing information on metformin effect on various cell lines was 
collected as mentions in section 1.3. The aim was to create a model that possible could help to 
predict the viability of the different cells when exposed to different concentrations and treatments 
times of metformin. This work was done in google collaborator and the coding library Pandas was 
used. The dataset was first uploaded here and then it was “cleaned”, which means rows in the 
dataset lacking very much information was removed. A decision tree regression model was used, and 
validation of the model was done by splitting the dataset intro a training set and a testing set. The 
training set was used to fit the model and the testing set was used as validation data. The model 
made in this project was far from precise in predicting outcomes, but was more of a training exercise 
for understanding how machine learning works, and see the possibilities of this kind of work when 
done correctly by someone with good skills in this subject.  
2.2.2 Media 
The composition of complete cell culture media used is listed in table 2.3. 
 
Table 2.3: All components to fix a DMEM complete media on a total volume of 562,22 mL, the result is a low 
glucose media (5 mM). 
Components Amount in mL  
Dulbecco’s Modified Eagle’s Media, without 
glucose, L-glutamine and sodium pyruvate) 
500 
Foetal bovine serum, heat inactivated, South 
American origin 
50 
Penicillin; Streptomycin solution 6,0/10,0 g/L 
100X 
5 
L-glutamine, 200 mM 5 
Glucose, 2,4 mM  2,22 
 
Foetal bovine serum is blood serum drawn from a bovine fetus and is one of the most used serum for 
growing cells in vitro in the lab, due to its high level of growth factors and low level of antibodies. 
This makes it usable for growing many different cell types. Penicillin is added to prevent bacterial 
growth in the cell culture, and glucose and glutamine are nutrients and amino acids the cells utilizes 
as an energy source and macromolecular synthesis respectively.  
2.2.3 Media replacement   
The cell media was changed every second day to ensure that the cells had enough nutrient. This was 
done in a sterile cabinet by aspirating the current medium and replacing it with 10 ml new DMEM 
complete medium pre-heated to 37°C.     
2.2.4 Cell passaging 
When the cell density in the culture flask (see figure 2.1) approach a certain confluency, they might 
start unwanted signaling that can interfere with experiments as well as stop growing and compete 
for space. The cells in this experiment was passaged routinely and the flasks the cells were contained 
in was changed once a week. 
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The cells were passaged when they approached 70-90% confluency. This was done in a sterile cabinet 
to avoid any contamination. All reagents and media used was heated to 37°C to match the 
temperature of the incubator the cells were contained in. The media in the flasks was aspirated and 
2 ml PBS was added for cleaning. The PBS was aspirated carefully to not harm the cells, and 1 ml of 
trypsin was added. The trypsin was let to react for a couple of minutes. A microscope was used to 
closely watch the trypsin work and to determine when it was time to stop the digesting by adding 4 
ml of complete DMEM media. The DMEM/trypsin mix was mixed using a pipette and then a volume 
of this was added to a new flask, or a certain volume was kept in the flask and the rest was removed, 
depending on the split ratio and if the cells needed a new flask. The flask was changed approximately 
1 time each week to keep a clean environment for the cells. At last, DMEM complete media was 
added to have a total volume of 10 ml in the flask.  
 
Figure 2.1: Cell culturing flask (Lifeline Cell Tech Team 2020). 
This figure shows a cell culturing flask like the ones used in this project and a pipette that can be used to add 
the DMEM media.  
 
2.2.5 Cell viability assay 
The alamarBlue cell viability assays were done in a sterile cabinet to avoid any contamination. In the 
first step the medium in the flask was aspirated and the cells were rinsed with 2 ml PBS. After 
removing the PBS, 1 ml of trypsin was added and let to work, time depending on cell line, but 
approximately 1-2 minutes. The process was closely watched using a microscope. When the trypsin 
had broken up adherent cells, 4 ml of DMEM complete media was added and the culture was mixed 
carefully with a pipette. The trypsin/DMEM mix was transferred to a 15 ml tube to keep the cells 
from adhering. The cell density was measured using Muse cell viability kit and if the density was low, 
the tube was centrifuged so dead cells and cell debris could be removed. After centrifugation the cell 
will appear as a pellet in the bottom of the tube, and thus the media containing dead cells and debris 
could be removed and new medium was added. The volume of new medium was calculated to adjust 
the cell concentration to 500 000 cell/ml, making the calculation for the dilutions used in the assay 
easier. Five dilutions were made, containing 10 000, 15 000, 20 000, 25 000 and 30 000, respectively, 
see figure 2.2. Three parallels of each dilution (10 µl) were seeded out on a 96 well plate. 110 µl PBS 
was seeded out in the remaining empty wells, except for the four outermost corners. The plate was 
left to incubate for 48 hours in a cell incubator at 37°C. 
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After incubation, 10 µl of 484 µM resazurin at 37°C was added to each of the three parallels of each 
dilution, mixing with the pipette or shaking the plate to mix the reagent with the cell cultures. 110 µl 
of a positive control containing autoclaved medium and resazurin was seeded out in the four empty 
outermost corners for the alamarBlue assay. The plate was left to incubate for 4 hours in the cell 
incubator at 37°C. After incubation the plate was read by a SpectraMax® Paradigm® Multi-Mode 
Microplate reader to measure the fluorescence at 540-590 nm and hence the cell concentration.  
Only alamarBlue assay was done for finding the cell density that showed the most accurate rising 
trend and should be used in the metformin experiment, both alamarBlue and CCK-8 assays was used 
in the metformin experiment. The CCK-8 assay is preformed the same way as the alamarBlue, except 
incubation time is two hours and one should measure the absorbance at 450 nm. 
 
 
Figure 2.2: Plate layout alamarBlue cell viability assay 
This figure shows the locations of the different concentrations of cell suspensions of three cell lines, only Mia-
Pa-Ca-2 and Panc-1 was used in this experiment. It also shows the four positive controls (it says medium not 
positive control, as the medium was seeded out first and then replaced with positive control) in the outermost 
corners and the rest filled with PBS. 
 
2.2.6 Muse® Count & Viability kit (200X) 
Before start 0.5 mL of cell sample were poured into an ependorftube. In a 1.5-mL microcentrifuge 
tube 10 µL of cell sample who were mixed by pipetting and 190 µL Muse® Count & Viability reagent 
were add, the dilutions factor was 20. The tube with both components were mixed well by vortexing 
so no purple color was left. The tube with sample was incubated in room temperature for 5 minutes 
before loading it into the instrument. All steps were shown at the screen on the instrument and the 
result were noted 
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2.3 Metformin trial 
2.3.1 Calculations  
The trial start with the calculations, all volumes were measured for three cell-lines whereas two were 
used in this trial. Metformin comes in powder form and was mixed with MQ-water to make the 250 
mM metformin stock. 
700 µL Metformin stock per cell-line:  
700 × 3 = 2100 𝜇𝐿 = 2,1 𝑚𝐿 
Two tests → 2,1 × 2 = 4,2 𝑚𝐿 
Metformin in grams:  
𝒏 = 𝑪 × 𝑽 
𝐶 = 250𝑚𝑀 = 0,250𝑀 
𝑉 = 4,2 𝑚𝐿 = 0,0042 𝐿 
𝑛 = 0,250 × 0,0042 = 0,00105 𝑚𝑜𝑙 
𝒎 = 𝒏 × 𝑴 
𝑛 = 0,00105 𝑚𝑜𝑙 
𝑀 = 129,16 𝑔/𝑚𝑜𝑙 
𝑚 = 0,00105 × 129,16 = 0,135618 𝑔𝑟𝑎𝑚 = 135,618 𝑚𝑔 
250 mM metformin in volume: 
𝑪𝟏 × 𝑽𝟏 = 𝑪𝟐 × 𝑽𝟐 
𝐶1 = 250 𝑚𝑀 
𝑉1 = 𝑋 
𝐶2 = 1, 5 𝑜𝑟 10 𝑚𝑀 







10𝑚𝑀 × 4200 𝜇𝐿
250𝑚𝑀
= 168 𝜇𝐿 
𝑉5𝑚𝑀 =
5𝑚𝑀 × 4200 𝜇𝐿
250𝑚𝑀
= 84 𝜇𝐿 
𝑉1𝑚𝑀 =
1𝑚𝑀 × 4200 𝜇𝐿
250𝑚𝑀





Table 2.3: Calculated values for making metformin/DMEM media solutions 
Metformin and media volumes for right concentrations, total volume 4200 µL.   
 Metformin in µL Complete media in µL 
10 mM 168 4032 
5 mM 84 4116 
1 mM 20 4180 
 
 
2.3.2 Preparation of plate 
The cells were measured using the MUSE count and viability kit (200X): depends on how much 
cells/mL it is, dilution after table 2.4 is needed.  
 
Table 2.4: Table of correct volumes of muse reagent contra cell suspension for measuring cell viability 
This table was collected from the website/protocol? of company that provides the muse count and viability 
machine and reagents. It shows what volume of the muse reagent to use for different concentrations of cell 
suspensions and what dilution factor this corresponds to (Luminex Corporation 2020a) 
Conc. Of orginal cell 
suspension 
Dilution factor Cell suspension 
volume 
Count and viability 
volume 
1 × 105 𝑡𝑜 1
× 106 𝐶𝑒𝑙𝑙𝑠/𝑚𝐿 
10 25 µL 225 µL 
1 × 106 𝑡𝑜 1
× 107 𝐶𝑒𝑙𝑙𝑠/𝑚𝐿 
20 10 µL 190 µL 
> 1 × 107  𝐶𝑒𝑙𝑙𝑠/𝑚𝐿 40 10 µL 390 µL 
 
If the density in the sample is low, it is possible to centrifuge the tube. It helps to remove some of the 
dead cells and debris, also it decreases trypsin in the sample. After centrifuging most of the viable 
cells will appear as a pellet in the bottom of the tube, all media over this pellet was aspirated off and 
new fresh media was added before the pellet was resuspended.  
Total viable cells in original sample = X, to adjust the cell concentration to 500 000 cell/mL, Y = 
volume of medium to add in the tube: 
𝑋
500 000
= 𝑌 𝑚𝐿  
When the tube contains 500 000 cells/mL, 840 µL was added to a new tube and 3360 µL Complete 
media was added (total 4200 µL). The final concentration was 10 000 cells/100µL.  









Figure2.3: Figure of the plate layout of the 96-wells plate used in metformin experiment 
This figure shows the placement of the controls and the three different metformin treatments. 10 000 cells of 
the Panc-1 and MIA-Pa-Ca-2 cell lines (1 cell liner per plate) was seeded out in each of the colored wells in the 
figure. After letting the cells adhere, medium was aspirated and the different treatments of control with 
medium, control with media and MQ water and three different metformin concentrations in medium (1 mM, 5 
mM and 10 mM) was added. The plate was incubated for 24 or 48 hours. In the blue wells alamarBlue reagent 




Control with distillated water was made as the highest concentration of metformin, table 2.3 showed 
168 µL of distillated water and 4032 µL Complete media was mixed and added in the wells. Figure 
2.3 shows place in plate.  
Control was the cells who only been exposed to media, positive controls was autoclaved resazurin 
and in the empty cells around the occupied wells were filled with PBS. Figure 2.3 shows place in 
plate.  
Stock concentration with metformin 
A tube with metformin and distillated water was made. Metformin was weighed to 135,6 mg and 4,2 
mL distillated water was added, the final concentration was 250mM.  
From the stock with 250mM metformin three new tubes was diluted to a concentration of 1, 5 and 
10 mM, total volume was 4200 µL in each tube, see figure 2.4.  
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Figure 2.4: Illustration of making dilutions of different metformin concentrations in DMEM media 
This figure shows an overview of how to dilute 250 mM metformin into 1 mM, 5 mM and 10 mM 
concentrations in DMEM media.  
 
Second day was all media aspirated and 100 µL new fresh media with metformin was added. Media 
with metformin solution was made the day before.  
Third (24 hours plate) and fourth day (48 hours plate) was all media with metformin aspirated and 
new fresh media was added. Four hours before the plate was read in SpectraMax Paradigm Multi-
mode microplate reader the blue wells in figure 2 was aspirated and 100 µL new fresh media mixed 
with 10 µL alamarBlue was added and then incubated.  
2,5 hours before the plate was read the pink wells in figure 2 was aspirated and 100 µL fresh media 
mixed with 10 µL CCK-8 was added before incubating until the reading of plate.  
When the plate was read it was done two times, first the alamarBlue wells was read at fluorescence 
at 590 nm, and after the CCK-8 wells was read at absorbance at 450 nm.  
 
3. Result  
3.1 Pancreatic cancer cell growth and optimal seeding density 
The pancreatic cell lines in this experiment were MIA-Pa-Ca-2 (Figure 3.1) and Panc-1 (Figure 3.2). 
Both cell lines survived, proliferated and was free for any contamination when contained in the 
DMEM complete low glucose media throughout the experiments. The routinely passaging when 
approaching approximately 70% confluency worked well for both cell lines. We found that the Panc-1 
cell line grew slower than MIA-Pa-Ca-2 and was therefore passaged at a lower ratio to make sure the 




Figure 3.1: MIA-Pa-Ca-2 
Microscope picture of the MIA-Pa-Ca cell line. The morphological features of MIA-Pa-Ca-2 are a longer form 
with sharp corners 
 
 
Figure 3.2: Panc-1 





To find the optimal seeding density to be used for drug treatment experiments we seeded different 
cell numbers in 96 well cell culture plates to be read using the alamarBlue viability assay. The first cell 
seeding results are shown in figure 3.3. Here we see that there is an increase in fluorescence 
according to increasing cell density in both MIA-Pa-Ca-2 and Panc-1.  
In this experiment it seemed like the MIA-Pa-Ca-2 reached a plateau with regards to the fluorescence 
at 10 000 cells/well that did not further increase in the higher cell numbers. The same trend was not 
seen for Panc-1 as there was a slight increase in fluorescence from 10 000 cells/well to 20 000 
cells/well. The standard deviation for the Panc-1 cell line showed that there was low variation in cell 
density in the three well parallels. The wells that should contain 25 000 and 30 000 cell/well was 
empty on the plate containing Panc-1 cells as there were not enough cells for the experiment.  
 
 
Figure 3.3: AlamarBlue cell viability assay results week 1 
Results from alamarBlue cell viability assays done on the cell lines Panc-1 and MIA-Pa-Ca-2. Both cell lines were 
seeded out on a 96-well plate in the densities 10 000, 15 000, 20 000, 25 000 and 30 000 cells/well. The cells 
were let to adhere and after this 10 µl of the reagent was added. The reagent was let to work for 4 hours. 
Fluorescence was measured at 540-590 nm. 
 
The second assay showed slightly different results from the first experiment where there was an 
increase in fluorescence according to cell density for the cell line MIA-Pa-Ca-2, see figure 3.4. The cell 
density rose evenly from the wells containing 10 000 cell/ well to the wells containing 30 000 
cells/well. In this experiment the Panc-1 fluorescence did not change much ranging from 10 000 
cells/well to the 30 000 cells/well. The standard deviation showed that the cell density of the 
































Figure 3.4: AlamarBlue cell viability assay results week 2 
Results from alamarBlue cell viability assays done on the cell lines Panc-1 and MIA-Pa-Ca-2. Cells were seeded 
out on a 96-well plate in the densities 10 000, 15 000, 20 000, 25 000 and 30 000 cells/well. The cells were let 
to adhere and after this 10 µl of the reagent was added. The reagent was let to work for 4 hours. Fluorescence 
was measured at 540-590 nm. 
 
The final cell seeding experiment was performed on MIA-Pa-Ca-2 cell line alone as there were issues 
with the Panc-1 cell seeding and these wells were not used for further assay analysis.  
This third assay confirmed that MIA-Pa-Ca-2 shows an increase in fluorescence according to cell 


































Figure 3.5: AlamarBlue cell viability assay results week 3 
Results from alamarBlue cell viability assays done on the cell line MIA-Pa-Ca-2. The cells were seeded out on a 
96-well plate in the densities 10 000, 15 000, 20 000, 25 000 and 30 000 cells/well. The cells were let to adhere 
and after this 10 µl of the reagent was added. The reagent was let to work for 4 hours. Fluorescence was 
measured at 540-590 nm. 
 
As we wanted to be within the sensitivity of the assay when performing our drug screening, we chose 
to use 10 000 cells/well for both cell lines in the continuing experiments.  
 
3.2 Metformin treatment in pancreatic cancer cell lines 
3.2.1 MIA-Pa-Ca-2  
All results were normalized to control containing DMEM media only. 
AlamarBlue and CCK-8 assay after metformin treatment, 24 hours plate MIA-Pa-Ca-2 
On the 24 hours plate for MIA-Pa-Ca-2 shows from week 1 and week 2 a similar pattern on both 
fluorescence at 590 nm with alamarBlue and on absorbance at 450 nm with CCK-8. This actively 
means that it is not much derivation on the two plates consider the seeding of cells in wells and the 
adding of alamarBlue and CCK-8. See figure 3.6. In week 2 CCK-8 assay there is a small increase in 
viability from the water control to the 1 mM metformin treatment. The standard deviation for both 
weeks is low, meaning that there is consistency in our set up of the plates.  





























   
Figure 3.6: Results from cell viability assay of the MIA-Pa-Ca-2 cell line after 24 hours of metformin treatment  
This figure shows two cell viability assays done on the MIA-Pa-Ca-2 cell line after treatment with 1 mM, 5 mM 
and 10 mM metformin for 24 hours. The experiment was done twice, week 1 and week 2. For each week two 
96-wells plates were prepared by seeding out 10 000 cell/ well of the MIA-Pa-Ca-2 cell line. There was prepared 
one control with DMEM media only, and one with DMEM media and MQ-water. For the alamarBlue assay 
positive control was added. Six parallels on each plate were treated with the different metformin 
concentration. Half of the parallels were treated with alamarBlue reagent, and the other three were treated 
with the CCK-8 cell viability reagent. The figure to the left shows the fluorescence measured at 540-590 nm 
after addition of alamarBlue reagent. The figure on the right shows the absorbance measured at 450 nm after 
addition of the CCK-8 reagent. The results were normalized to the DMEM only control. 
 
AlamarBlue assay after metformin treatment, 48 hours plate MIA-Pa-Ca-2 
In the 48 hours metformin treatment there is a sharp decline in viability at the 5mM metformin 
concentration for MIA-Pa-Ca-2 which further decreases at the 10mM metformin concentration, see 
figure 3.7. Week 1 shows a larger decrease in alive cells when metformin concentration gets higher 
than week 2, especially after 1 mM.  
CCK-8 assay after metformin treatment 48 hours plate MIA-Pa-Ca-2 
Water control and 1 mM for both weeks are following the same curve, then it’s a big jump from 1 
mM to 5 mM and it is a big difference between week 1 and 2. From week 1 the metformin 
concentration from 5 mM to 10 mM have almost the same viability of cells, but for week 2 there is a 

























































   
Figure 3.7: Results from cell viability assay of the MIA-Pa-Ca-2 cell line after 48 hours of metformin treatment  
This figure shows two cell viability assays done on the MIA-Pa-Ca-2 cell line after treatment with 1 mM, 5 mM 
and 10 mM metformin for 48 hours normalized to control containing DMEM medium only. The experiment was 
done twice, week 1 and week 2. For each week two 96-wells plates were prepared by seeding out 10 000 cell/ 
well of the MIA-Pa-Ca-2 cell line. There was prepared one control with DMEM media only and one with DMEM 
media and MQ-water. Positive control was added for the alamarBlue assay. Six parallels on each plate were 
treated with the different metformin concentration. Half of the parallels were treated with alamarBlue 
reagent, and the other three were treated with the CCK-8 cell viability reagent. The figure to the left shows the 
fluorescence measured at 540-590 nm after addition of alamarBlue reagent. The figure on the right shows the 
absorbance measured at 450 nm after addition of the CCK-8 reagent.  
 
A picture was taken at the wells with some deviation after the plate was read, see figure 3.8 and 3.9. 
The pictures show a large bubble in the left corner which can act to obscure the reading, see figure 
3.8. The other wells had a more evenly spread in the cells, as shown in figure 3.9 are more compact 


























































Figure 3.8: Microscope picture of MIA-Pa-Ca-2 in a 96 wells plate 
This figure shows a picture of one of the wells who had a deviation who was visible for the eye to see. In the 
left down corner, it shows a big bubble who can be the result of some deviation in the measurement and made 
a bigger standard deviation in the graphs.  
 
 
Figure 3.9: Microscope picture of MIA-Pa-Ca-2 cell line on a 96 wells plate 
This figure shows a visible deviation for the eye to see with the lighter color in this well. As shown the cells look 
more compact and in a larger colony in the upper part of the well, this can be the result of the deviation in the 
measurement and made a bigger standard deviation in the graphs.  
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To sum up everything that has been stated so far, this research shows the metformin have an impact 
on MIA-Pa-Ca-2 cells, when the metformin concentration increases up to 10 mM the cells alive are 
decreased.  
3.2.2 Panc-1 cells 
All results were normalized to control. The week 1 plate lacked control with DMEM media only and 
was therefore normalized to the control containing DMEM medium and MQ-water.   
Alamarblue assay after metformin treatment, 24 hours plate Panc-1 
The first week the results showed a decrease in viability from the control with MQ-water to the first 
metformin treatment (1 mM). From 1 mM to 5 mM the viability decreased, but from 5 mM to 10 mM 
it increased as shown in figure 3.10. The second week the viability increased when treated with 1 
mM compared to the MQ-water control, but then decreased continuously from 1 mM to 10 mM 
metformin treatment. The standard deviations were very high in the first assay compared to the 
second one.  
CCK-8 assay after metformin treatment, 24 hours plate Panc-1 
In this assay the viability decreased from the MQ-water controls to the first metformin treatment of 
1 mM in both weeks. The first assay done (week 1) had a decrease in viability from 1 mM to 5 mM, 
but likewise the alamarBlue assay, the viability increased from the wells treated with 5 mM to 10 
mM. The second week the viability decreased continuously from 1 mM treatment to 10 mM 
treatment. The standard deviations were higher for the second week assay compared to the first 
week, especially in the three parallels containing 5 mM metformin, see figure 3.10.  
  
Figure 3.10: Results from cell viability assays of the Panc-1 cell line after 24 hours of metformin treatment 
This figure shows two cell viability assays done on the Panc-1 cell line after treatment with 1 mM, 5 mM and 10 
mM metformin for 24 hours. The experiment was done twice, week 1 and week 2. For each week two 96-wells 
plates were prepared by seeding out 10 000 cell/ well of the Panc-1 cell line. There was prepared one control 
with DMEM media only (missing on week 1 plate due to errors), and one with DMEM media and MQ-water. For 
the alamarBlue assay positive control was added. Six parallels on each plate were treated with the different 
metformin concentration. Half of the parallels were treated with alamarBlue reagent, and the other three were 
treated with the CCK-8 cell viability reagent. The figure to the left shows the fluorescence measured at 540-590 
nm after addition of alamarBlue reagent. The figure on the right shows the absorbance measured at 450 nm 
after addition of the CCK-8 reagent. The results for week 1 are normalized to control with MQ-water, and the 
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AlamarBlue assay after metformin treatment, 48 hours plate Panc-1 
The first assay done (week 1) showed a small decrease in cell viability from the control with MQ-
water to the first metformin treatment of 1 mM. It had the highest decrease in cell viability from 1 
mM to 5 mM metformin treatment, and from 5 mM to the 10 mM the cell viability was almost 
constant, see figure 3.11. The second assay done also had a decrease in viability from MQ-water 
control to the 1 mM metformin treatment. This assay also had the highest decrease in viability going 
from 1 mM treatment to 5 mM treatment, see figure 3.11. The cell viability decrease flattens out and 
is almost constant from 5 mM to 10 mM of metformin treatment, like the first week. The standard 
deviations were very high, especially for the week 2 assay and shows that there was a lot of variation 
between the three parallels.  
CCK-8 assay after metformin treatment 48 hours plate Panc-1 
The first assay done (week 1) had a large increase in cell viability in the control parallels with media 
and MQ-water to the first metformin treatment (1 mM), see figure 3.11. From 1 mM to 5 mM 
treatment the viability decreases a lot in week 1, but from 5 mM to 10 mM the viability decreases 
less in this assay. The second assay (week 2) have a continuously linear decrease in cell viability from 
the control with MQ-water to the 5 mM metformin treatment, but also here the curve flattens out 
going from 5 mM to 10 mM, see figure 3.11. The standard deviations were relatively low in the week 
1 assay, but in the week 2 assay there was a lot of variation between the three parallels. The 1 mM 
wells in week 1 had the highest standard deviation, see figure 3.11.   
 
  
Figure 3.11: Results from cell viability assay of the Panc-1 cell line after 48 hours of metformin treatment  
This figure shows two cell viability assays done on the Panc-1 cell line after treatment with 1 mM, 5 mM and 10 
mM metformin for 48 hours normalized to control containing DMEM media only. The experiment was done 
twice, week 1 and week 2. For each week two 96-wells plates were prepared by seeding out 10 000 cell/ well of 
the Panc-1 cell line. There was prepared one control with DMEM media only (missing in week 1), and one with 
DMEM media and MQ-water. Positive control was added for the alamarBlue assay. Six parallels on each plate 
were treated with the different metformin concentration. Half of the parallels were treated with alamarBlue 
reagent, and the other three were treated with the CCK-8 cell viability reagent. The figure to the left shows the 
fluorescence measured at 540-590 nm after addition of alamarBlue reagent. The figure on the right shows the 
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4. Disscussion  
4.1 AlamarBlue cell viability assays 
Week 1 assay MIA-Pa-Ca-2 
This cell line had high concentration of cells, but some unexpected variation was observed, see figure 
3.3. One should expect a rising cell viability from 10 000 to 30 000 cell/wells, but the results show a 
higher cell viability in the 10 00 cell/well than in the 15 000 cells/well. The cell viability also decreases 
continuously from the 20 000 cell/well to the 30 000 cell/well. This is most likely due to not mixing 
the cell suspension enough before seeding out on the plate. It can also be due to more proliferation 
in some wells than others. The standard deviations show some variations, but none of the parallels 
differed so much that they had to be removed.    
Week 1 assay Panc-1 
The results show that the Panc-1 assay from week 1 had very low cell density, see figure 3.3. This 
could be due to errors like seeding out less cells than 10 000 cell/well. There might have been done 
mistakes in calculations, probably in the first steps as there is a rising cell viability even if it has lower 
density than expected and compared to the MIA-Pa-Ca-2 cell line. Other errors can be that the cell 
suspension was not mixed properly so the cells sink to the bottom of the tube and hence is not 
transferred to the plate. The standard deviations show that there were relatively low variations in 
the parallels.   
The Panc-1 was also lacking the two last columns on the plate (25 000 cell/well and 30 000 cells/well) 
as there was not enough cell suspension, see figure 3.3. When adjusting the concentration to 
500 000 cell /ml after centrifugation, the volume of added medium was not enough to complete the 
plate due to low confluency in the flask when starting the experiment. The cells should not have 
been passaged at a low ratio the days before the experiment, but this was done. 
Week 2 assay MIA-Pa-Ca-2 
This assay went very well for the MIA-Pa-Ca-2 cell line and shows a continuously rising cell viability 
and have low standard deviations witch one exception in the 15 000 cell/well. Here there was some 
variation between the three parallels. These results show that the calculations and the techniques 
used when preparing the plate was done correct, see figure 3.4. 
Week 2 assay Panc-1 
In this assay the Panc-1 cell line had much higher density of cells compared to the first week. This 
implies that there was done mistakes in the first assay when seeding out the cells. This second assay 
had some unexpected values in the 10 000 cells well and the 30 000 cells well. This is most likely due 
to wrong techniques in pipetting and not being completely exact when making the dilutions. There is 
also a possibility that the cells have proliferated more in some wells than others, or proliferation 
have been inhibited by unknown contamination. From the wells with 15 000 cells to 25 00 cells there 
was a rising trend in cell viability, see figure 3.4.  
Week 3 assay MIA-Pa-Ca-2 
In this assay the MIA-Pa-Ca-2 cell line had a continuously rising cell viability. The largest standard 
deviation was seen in the three parallels containing 10 000 cells/well and 20 000 cells/well, see figure 
3.5. This can be due to seeding out the suspension unevenly (not mixing enough) so that some of the 
wells contained less cells than others. It can also be contamination that prevents cell proliferation or 




The optimal seeding density was 10 000 cell/well for both cell lines and hence this concentration was 
used in the metformin experiment.  
 
4.2 Metformin trial results 
Both two cell lines MIA-Pa-Ca-2 and Panc-1 was affected by the metformin treatment as the cell 
viability decreased as the metformin treatment increased. The most effective treatment time was 48 
hours. There were some deviations in the results, most likely due to errors done under preparation 
of the plates. 
4.2.1 Mia-Pa-Ca-2 
MIA-Pa-Ca-2 metformin trial discussion 
With the result from these two weeks it looks like metformin have an impact on MIA-Pa-Ca-2 cells. 
The 24-hour metformin treatment shows for both weeks, that there is little effect on viability, which 
could mean that the metformin has not started to affect the cells yet. It looks like the seeding out of 
the cells were even in each well. The differences from 1mM metformin to 5 mM metformin is not 
that big, but it is a small decrease. From 5 mM to 10 mM metformin it is a little bigger decrease but 
still not much. On the CCK-8 test it looks like the cells got more affects from the control with water 
than from 1 mM metformin, but de standard deviation is a little bigger from both weeks, especially 
week 2 and that can have affect on the result.  
The 48-hour metformin treatment start the same and then it shows a deviation that increase in size 
until 5 mM and then decrease at 10 mM again.  When the plate had incubated enough it was 
possible to see some deviation in the colors in the wells, and some closer look in the microscope 
shows as the picture says in the result that it was a bubble in the corner of one well and some 
strange growth on another well. It can indicate the bigger deviation in the result for the 10 mM wells 
because both deviations were therefrom.   
From week 1 the standard deviation isn’t visible in the graphs it’s because they were so small. The 
standard deviation from week 2 are a little bit larger which can mean the either the cells weren’t 
spread in the wells evenly or when alamarBlue/CCK-8 was added it wasn’t mixed good enough so it 
wasn’t equal spread in the wells. It is also hard to say if the cells were growing like that before the 
metformin was added or if it happened when metformin start to affect the cells, the wells were only 
checked after they had incubated.  
In the CCK-8 assays there was bigger standard deviation than in the alamarBlue assays, this might be 
because CCK-8 is more sensitive than alamarBlue. 
 
4.2.2 Panc-1 
Panc-1 metformin trial discussion 
Based on this experiment the Panc-1 cell line seems to be affected by metformin as the viability 
decreases when treated with metformin in vitro. The dose of metformin that decreased the cell 
viability the most was 10 mM. This seems to be a trend in most of the Panc-1 cell viability assays 
after addition of metformin. The most dramatic decrease in cell viability was shown going from 1 mM 
to 5 mM, but there was also some further decrease from 5 mM to 10 mM in most of the assays. Due 
to high variation and some errors done when preparing the plates, it will be hard to conclude this. 
More assays should be done before making a conclusion. From the results it shows that in the 
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alamarBlue assay week 2 and the CCK-8 assay week 1 the cell viability increases when treated with 1 
mM metformin compared to the control. This does not seem logic as metformin is expected to 
decrease viability and does decrease viability in most of the results with 1 mM compared to control, 
hence this is most likely due to errors done when preparing the plate. There might have been seeded 
out more than 10 00 cell/well. When pipetting cell suspension into the wells the suspension should 
be mixed carefully with the pipette, so the cells does not sink to the bottom of the tube. This might 
cause this unexpected rise in cell viability as the control might have less cells then the wells treated 
with 1 mM metformin. Also, the cell proliferation might differ between the wells and cause 
variations. Other errors can be that the tube containing metformin mixed in medium was not mixed 
properly so the actual concentration of metformin was lower than 1 mM. The variation seen in the 
results, especially in the week 2 assays can also be caused by not mixing the metformin solution or 
the cell suspension enough.  
All the week 1 assays lacked control with DMEM media only, but the week 2 assay showed that MQ-
water had little effect on the cells, so this result was normalized to the MQ-water control. The plates 
that was treated for 48 hours had more decrease in viability than the ones treated for 24 hours, 
hence longer treatment time seems more effective. The week 1 alamarBlue assay had a relatively 
high increase in viability going from 5 mM to 10 mM, this can also be due to errors. In all the other 
assays the curve flattens out going from 5 mM to 10 mM metformin treatment. This induce that the 
most effective concentration of metformin is 5 mM for the Panc-1 cell line, based on these results. 
Other errors that might have affected the results is that there was not added enough reagent 
(alamarBlue/CCK-8). The reagent was mixed in DMEM media before it was added to the wells. If this 
solution was not properly mixed there can be variations in the concentration of added reagent which 
affect the results. When adding the CCK-8 reagent there was a small bubble in the week 1 48 hours 
plate. This can cause errors when measuring absorbance. There can also have been contaminations 
like small particles from clothes etc. that can have affected the behavior of the cells and hence the 
results.  
MIA-Pa-Ca-2 and Pan-1 are affected by metformin treatment 
Both cell lines were affected by the drug, but the MIA-Pa-Ca-2 cell line had the most decrease in 
viability when treated with metformin. The MIA-Pa-Ca-2 also had lower standard deviations 
compared to the Panc-1 and had a more accurate trend in the results. This was most likely due to 
more errors done when executing the experiments for the Panc-1 cell line.   
This is a good indication that metformin can work as a cancer treatment but results like these alone 
are far from enough to conclude if it is worth using metformin on cancer patients. Cells kept in vitro 
in a controlled environment like the cell lines in this experiment may act very different then the same 
cell lines in vivo, in tumors. The human body are highly complex and cells in the body are a part of a 
signaling network that affect the cells, hence differently than cells kept in vitro. In vivo experiments 
are needed to find out if a drug can be used for certain purpose or not.  
Metformin on the other hand is a drug that are already approved for medical use as it is widely used 
to treat type 2 diabetes. It is considered highly safe and with little side effects. This makes it easier to 
do human trials to see if the drug might have other beneficial effects than the already known effects. 
Metformin is widely studied and there are numerous of published scientific articles on its effects, 
many of these are studies on metformin’s effect on cancer. In this project 66 different scientific 
articles on metformin’s effect on various types of cell lines were included, and most of these articles 
focused in on cancer. Many of these articles concluded that metformin might have a beneficial effect 
on cancer cells.   
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4.3 Database creation and machine learning 
Extracting information from previous experiments can be a good way to improve one’s own research 
and can be a way to validate results as well as getting new knowledge on a subject. As done in this 
experiment, extracting what information we though would be important, and organizing it so it could 
be applied to a machine learning algorithm is a very effective way to store knowledge and also make 
predicting models based on the previous experiments done. As beginners in the machine learning 
and coding world the model made in this project did not give good predictions, but if correctly done, 
this way of doing research might be the future. 
The knowledge is out there, finding good sources on metformin’s effect on cancer cells was not 
difficult. What was challenging was extracting the information and get it ready for the machine 
learning part. Using machine learning and artificial intelligence to improve research seems to be the 
future as the technology improves rapidly. Maybe there should be a golden standard for how to 
design a publishment, so it is more appliable for machine learning algorithms? And making an online 
machine learning library of extracted information on different subjects could be very useful. Articles 
that are already published should also be in this library so there is lots of work needed to make this 
possible.  
 
5. Conclusion and future perspectives  
From this experiment alone the conclusion is that metformin does influence pancreatic cancer cell 
lines as it decreases their viability. Based on the results from this experiment the dosage that seemed 
to have the best effect on both cell lines was 10 mM metformin and the most effective treatment 
time for decreasing viability was 48 hours.  
Experiments like the ones done in this project is a useful tool when testing drugs as there is no risk 
factor as in experiments done on animals or humans. To further test metformin effect in pancreatic 
cancer cell line the experiment should have been done several times, but there was not time for this 
in this project.  
When it comes to metformin and its effect on cancer, one could use machine learning to predict how 
different cancer cells will be affected by the drug, in vitro and in vivo. To get the best predictions one 
should gather as many as possible of previous experiments and knowledge and have someone 
capable of creating a good machine learning model. The predictions of the model should also be 
verified upon results of traditional experiments, and should not be used to make decisions alone, but 
be a tool for improving decisions. 
Also, it could be interesting to create a model that simulates the human body and tumors, this could 
be very helpful when testing new medicines and treatments. This might be very challenging because 
the human body is highly complex, and all its functions are not fully understood yet, but this kind of 
models could contribute to more effective and safe testing of new drugs. Computers are extremely 
effective and can run many tests simultaneously, including previously research. A problem with this 
kind of models is that researchers might discover new functions of the human body and then the 
model can be wrong, but if the model is used as a tool combined with standard research methods, 
these errors can be discovered. Humans can react different to treatments as well, so the model 
might not fit for everyone, but still would be a useful tool in general. Models could also be 
personalized to a specific disease and specific tumors. Machine learning seems to be more used in 
many different fields as well as in science and holds very interesting possibilities for the future.  
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